Recombinant human interleukin-11 (Xiamen Amoytop Biotech)

重组人白介素-11（厦门特宝生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-11 (Xiamen Amoytop Biotech)
Drug Alias NameTopmega重组人白细胞-11Oprelvekin biosimilar (Xiamen Amoytop Biotech)Interleukin-11 (Xiamen Amoytop Biotech)特尔康 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionThrombopoiesis stimulantsInterleukin 11 receptor alpha stimulants
TargetsInterleukin 11 receptor alpha
Therapy Area/IndicationsThrombocytopenia
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaThrombocytopenia
Original Approved Country/TerritoryMainland China
Original Approved Date2005/04/11
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesXiamen Amoytop Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXiamen Amoytop Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsThrombocytopenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AC02
Related LinksN/A